PT-141

What it is

PT-141 is the literature name for bremelanotide, a peptide that acts as a melanocortin-receptor (MCR) agonist. It works differently from vascular-focused approaches: instead of acting on blood flow directly, it activates presynaptic MC4 receptors concentrated in the hypothalamus, an area central to the brain’s regulation of sexual desire (The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder, PMID 33455598). The FDA-approved brand version of bremelanotide, Vyleesi, is indicated specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and is not approved for use in men or for postmenopausal women.

Compounded PT-141, the form available through this telehealth pathway, is not FDA approved; only Vyleesi carries FDA approval, and only for its specific approved population and indication. Van Peptides frames PT-141 as a sexual-wellness and libido-focused option, not as a male-enhancement product, and candidacy is assessed individually rather than assumed. It is available after a licensed-provider evaluation and, if a prescription is issued, is compounded through a US-licensed compounding pharmacy.

Van Peptides connects patients with an independent network of US-licensed providers who evaluate whether PT-141 fits your history and goals, regardless of sex or the specific concern you bring to your intake. We do not diagnose, prescribe, or dispense, and we do not employ the providers or the pharmacy.

What the literature has explored

The clinical trial program supporting Vyleesi’s approval studied bremelanotide specifically in premenopausal women with acquired, generalized HSDD, using patient-reported measures of desire and related distress (An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist, PMID 16839319). The proposed mechanism, activation of MC4 receptors in the medial preoptic area leading to increased dopamine release, is thought to act on the brain’s excitatory pathway for sexual response rather than on peripheral vascular tissue (neurobiology review, PMID 33455598).

Interest in bremelanotide outside its approved population, including in men or in other sexual-wellness contexts, draws on this same melanocortin mechanism, but that use has not been evaluated with the same trial rigor as the HSDD program that led to Vyleesi’s approval. We are not aware of a comparable FDA-reviewed trial program supporting use outside that approved indication, and outcomes are individual. A licensed provider is the right person to discuss whether the studied mechanism is relevant to your specific situation.

We describe the approved brand-drug facts because they are accurate and relevant, but we do not extend that approval status to compounded PT-141, and we do not frame this page around performance claims that the underlying trial program never set out to measure.